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Abstract 
Background and aims: Opioid formulations with properties to deter abuse (abuse-deterrent 
formulations; ADFs) have been developed as one response to the prescription opioid ‘epidemic’. As 
for all medicines, ADFs undergo evaluation of safety and efficacy prior to registration for marketing. 
Yet, reduced extra-medical use (the primary intended outcome of ADFs and reason for their 
introduction) can only be established in post-marketing observational studies, comparing them to 
opioid formulations without abuse-deterrent properties. This has implications for various features of 
study design and analysis. We discuss proposals for the design, conduct, governance, and reporting 
of post-marketing studies on the effectiveness of pharmaceutical and opioid ADFs. 
Methods: A review of current guidance documents, public workshops and forums, and our own 
experience with post-marketing studies of ADFs. 
Results/Conclusions: Research questions for post-marketing studies on abuse-deterrent 
formulations (ADFs) of opioids should reasonably be framed around detecting any likely intended or 
unintended clinical and/or meaningful changes in specific aspects of extra-medical use (e.g., 
injection use) and harms. Outcomes reported by prevalence and frequency of occurrence and 
disaggregated by specific product and route of administration can illustrate magnitude of ADF 
impact. We argue that a multi-faceted approach is required, using data from both general 
population and sentinel high-risk cohorts, and from primary and secondary data sources. The 
comparator (historical non-ADF formulation of that opioid, equivalent current generic or similar 
opioid product), duration of monitoring, and analytical approach require justification and should be 
sufficient to add weight to conclusions of causality. To maximise transparency, we recommend 
explicit declarations of funding and conflict of interest, establishment of an advisory committee, 
publication of study protocol, and access to all study results.    
  
 
INTRODUCTION 
Pharmaceutical opioid use carries a risk of dependence, and this risk is increased when 
pharmaceutical opioids are used extra-medically (i.e., outside of a medical professional’s advice; 1). 
Development of abuse-deterrent formulations (ADFs) of pharmaceutical opioids is one response to 
increased pharmaceutical opioid extra-medical use and harms in North America (2, 3). The primary 
intent of ADFs is to reduce specific aspects of extra-medical use by targeting certain behaviours, 
such as tampering and use via routes of administration other than as intended (e.g., crushing to 
snort or inject tablet formulations intended for oral consumption).  
 
Definition and Mechanisms of ADFs 
ADFs make these behaviours less rewarding or more difficult through: 
1. physical or chemical barriers (e.g., formulations containing hydrogelling agents which resist 
crushing or dissolving); 
2. antagonist/agonist combinations (e.g., opioids with corresponding antagonist such as 
naloxone or naltrexone released on tampering); 
3. specific delivery systems (e.g., opioid implants or depot injections); 
4.  prodrugs (e.g., opioid released after parent drug ingested and metabolised through 
stomach enzyme, i.e., orally); and/or  
5. aversive components (e.g., aversive agent like sodium lauryl sulfate released on tampering) 
(4).  
 
Abuse deterrence does not infer complete prevention of extra-medical use and ADFs are unlikely to 
deter the most common form of extra-medical use, where opioids are used via the intended route of 
administration but in excess of the prescribed dose (4, 5). Thus, ADFs form one strategy in what 
needs to be a multifaceted response targeted at curbing pharmaceutical opioid use and harms (6). 
Indeed, each ADF must be individually evaluated in terms of risk-benefit, reinforced by recent 
removal from the market of reformulated products with ADF properties with insufficient evidence to 
support ADF labelling, and post-marketing data indicating greater harms from extra-medical use (7). 
Critical to evaluating the possible role of ADFs as part of this response is having high-quality robust 
data regarding the nature and extent of impact these formulations have in reducing extra-medical 
use and associated harms. 
 
 
 
 
Contemporary Post-Marketing Surveillance and ADFs 
Like any prescribed medicine, ADFs must undergo post-marketing assessment. Traditional post-
marketing surveillance of activities focus on pharmacovigilance: safety as typically assessed by 
adverse event reporting (8). Although safety remains a primary concern, there is increasing 
recognition that passive systems of adverse event detection (like adverse event reporting) fall short, 
in that they do not have the capacity to quantify the true magnitude of risk from a particular 
medicine (9). Contemporary systems that harness administrative and other sources of data (e.g., 
prescription monitoring programs, analyses of administrative and other data) have the capacity to 
quantify risk, with certain regulatory bodies (e.g., the US Food and Drug Administration; FDA) 
requiring active and extensive monitoring of outcomes after the medicine is approved for marketing 
(10).  
 
Unlike other medicines, ADFs are developed specifically to minimise unintended patterns of opioid 
use that are known to be harmful. Randomised controlled trials can establish pharmaceutical opioid 
safety and efficacy. Yet, the latter is limited to the assessment of the pharmacological impact of the 
opioid. Reductions in extra-medical use associated with a specific formulation can only be 
established in post-marketing observational studies and require comparison to opioid formulations 
without abuse-deterrent properties. This also has implications for the design and conduct of ADF 
post-marketing studies. 
 
Current Post-Marketing Surveillance Guidance for ADFs 
To our knowledge, only the US has a regulatory framework regarding the level of pre- and post-
marketing evidence required for industry to label a product as an ADF (4). Two major documents 
provide guidance: the FDA guidance (4) and the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT), written by a group comprising representatives from 
government organisations, pharmaceutical companies and research organisations (11). Both sources 
outline recommendations for study design. However, neither addresses issues around study 
conduct, governance, and reporting. This issue is particularly pertinent given the need for rigorous 
review of evidence used to inform medicine regulation, and emphasis on transparency and 
reproducibility of findings.   
 
 ‘For Debate’ Objectives and Sources of Information 
In this ‘For Debate’ piece, we examine the complexities of this issue, proposing a framework for 
study design, conduct, governance, and reporting of pharmaceutical opioid ADF post-marketing 
 
studies. ADFs are a relatively new strategy (the US FDA has approved labelling describing abuse-
deterrent properties for eight opioids, including oxycodone and morphine formulations; 12), and 
there has been substantial maturing of this field of research in the wealth and quality of studies 
conducted (13-31). Yet, the opportunities for new developments are great, and there is growing 
momentum for more comprehensive guidance for such studies. This call for further guidance is also 
driven by government regulators charged with making decisions regarding product registration and 
public subsidy (10, 32, 33), and heightened by the withdrawal of ADFs from the market based on 
post-marketing evidence of increased harms (7, 34). Thus, the discussion outlined in this manuscript 
is timely, and integral to the shaping of this field of research moving forward. Prior and current post-
marketing studies may use some components of the suggestions below, but we believe it is 
important to synthesise current viewpoints and provide clarity in highlighting the best approaches 
for the field into the future.  
  
The proposals we make here draw upon the existing guidance noted above (4, 11), public workshops 
and forums on opioid ADFs (35), discussions of transparency for pharmaceutical clinical trials and 
observational studies (36), and our own experience conducting post-marketing studies of 
pharmaceutical opioid ADFs (20, 37-39). We also summarise key features of post-marketing studies 
of ADFs identified in a recent systematic review of ADF effectiveness and value (5), which is available 
online in full (https://icer-review.org/announcements/final-adf-report/). Our commentary does not 
cover all aspects of the research process; instead, we have focused on the domains related to study 
design, conduct, and reporting where guidance and standards are being debated in the 
aforementioned contexts.  
 
ADF POST-MARKETING STUDY DESIGN COMPONENTS 
ADF Post-Marketing Study Research Question 
Post-marketing studies of pharmaceutical opioid ADFs assess whether an ADF results in meaningful 
changes in extra-medical use and harms. Given the intent of ADFs, the research questions and 
hypotheses might reasonably be framed around detecting a reduction in specific practices, such as 
insufflation or injection, other aspects of extra-medical use (e.g., attractiveness in the illicit opioid 
market), and harms (4). Some studies have identified the intended consequence of ADF introduction 
(i.e., lower levels of tampering with the ADF relative to the comparator) coupled with unintended 
consequences (e.g., switching to extra-medical use of other pharmaceutical opioids and/or heroin 
use; 5). Consequently, it may be appropriate to operationalise the research question to detect any 
likely intended or unintended clinical and/or practically significant changes associated with ADF 
 
introduction (i.e. an increase or decrease in these indicators, not necessarily restricted to the use 
and harms of the ADF product itself).    
 
Outcomes 
As aforementioned, the core outcome of post-marketing studies comprises the patterns of opioid 
use targeted by the ADF, yet other aspects of extra-medical use and harms are also important to 
monitor for demonstrating both ADF effectiveness and safety (for elaboration, see Figure 1). In 
terms of monitoring broader unintended consequences of ADFs, we argue that post-marketing 
studies should also measure total population-level opioid exposure given possible changes in overall 
utilisation, and market features (e.g., street price) given the association with rates of extra-medical 
use and harms (5, 40). These outcomes can be split into various facets (see Figure 1). Each of these 
can contribute to evidence regarding ADF impact, and we believe are important in weighing up risk 
and benefit (4, 11).  
 
The outcomes specified in Figure 1 should be disaggregated where possible by: i) the specific ADF 
and relevant comparators, and ii) use via any route and route-specific (e.g., intravenous versus 
intranasal use) (4). There may be instances where outcomes cannot be disaggregated by specific 
product or route of administration, and it may be appropriate to describe data by the smallest 
possible unit (e.g., by active ingredient). To illustrate magnitude of ADF impact, outcomes can be 
quantified by their prevalence and frequency of occurrence where possible. This depth of 
information captures the scale of change associated with the ADF and facilitates comparison to 
comparator non-ADF formulations.  
 
Design, data sources and populations 
Although not an exhaustive list, key study designs for post-marketing studies of pharmaceutical 
opioids comprise i) time series: where exposures and outcomes are observed at multiple time points 
from the same or different individuals (e.g. the number of prescriptions per month); ii) cross-
sectional: where exposures and outcomes are collected at a single point in time or serially (not 
necessarily at equally-spaced intervals) from the same or different individuals (e.g. surveys of people 
who inject drugs); and iii) cohort: where exposures and outcomes are observed across multiple 
points of time (not necessarily at equally-spaced intervals) from the same individuals (e.g. people 
prescribed pharmaceutical opioids followed longitudinally). Other study designs (e.g., self-controlled 
designs) might also be considered (41)  
 
 
These study designs can utilise different types of data, specifically primary data collected and 
collated for the purpose of the study, or secondary data collected for other purposes that can 
provide information on the key outcomes of interest (typically administrative data, e.g., hospital 
separations, police drug seizures). They can also use data from different samples: representative of 
the general population or of sentinel high-risk populations (i.e., a surveillance group in which 
emerging trends are most likely to be observed). The latter may comprise those populations most 
likely to engage in extra-medical opioid use, where we are most likely to observe the impacts of 
ADFs (e.g. people who are opioid-dependent, people who use illicit drugs, people who inject drugs). 
 
Study design, data type and population can determine the degree to which a post-marketing study 
can:  1) identify events in the total population (signal detection) versus individuals at elevated risk 
(risk management); 2) identify rare events; 3) detect change in events; 4) identify changes in events 
at the population- versus individual-level, and 5) provide timely information. In Table 1, we provide a 
matrix of proposals regarding the degree to which these five objectives can be achieved using 
various study designs, data types, and populations. Indeed, ADF post-marketing studies have an 
additional level of complexity given the range of outcomes and levels of disaggregation by product 
and route of administration, as well as potential jurisdiction-level differences in ADF policy and data 
availability. Thus, a multi-faceted approach using various study designs, population and sources may 
be appropriate.  
 
We argue that data may need to be obtained from both general population and sentinel high-risk 
samples, and from primary and secondary data sources. General population data permit estimates 
of population level exposures and risks of outcomes; sentinel high-risk population data reflects 
outcomes in the group at greatest risk of reporting extra-medical use of ADFs or outcomes. Primary 
data collection can be designed to permit disaggregation by drug, dose, and route, providing 
detailed pharmaceutical opioid exposure and extra-medical use data. This level of information is 
typically not available in secondary data. Despite its limitations (42, 43), secondary data (particularly 
population-wide datasets) are also important to post-marketing studies, having greater capacity to 
capture rare events relative to primary data. For example, changes in opioid overdose are more 
likely to be detected in routinely-collected ambulance data than in survey data given the large 
sample size necessary to detect change in this low incidence event (38). The proposed capacity of 
various secondary data sources to measure the core outcomes in ADF post-marketing studies is 
outlined further in Table 2. 
 
 
In considering a multi-faceted approach to ADF, we highlight two particular combinations of study 
design, data type, and population: i) time-series study of the general population using secondary 
data; and ii) cohort study of sentinel high-risk population using primary and/or secondary data (Table 
1). Both capture events over time, critical where the comparator may comprise a counterfactual 
scenario (i.e., an alternative scenario where the ADF was not available, e.g., prior to introduction). 
One advantage of prospective cohort studies of sentinel high-risk populations is that they can collect 
rich information on clinical characteristics, other health service use, and adverse outcomes to 
contextualise changes apparent with ADF introduction. Adapting existing general population cross-
sectional surveys and establishing online sentinel high-risk sample surveys have also been discussed 
as key components of ADF post-marketing monitoring. However, concerns around 
representativeness of sentinel high-risk samples have been noted given the diversity of groups at 
high-risk for extra-medical use (e.g., populations reporting chronic non-cancer pain; opioid 
dependence; illicit opioid use; injecting opioid use; see 35 for further discussion).  
 
Choice of comparators 
To answer the research question, it is ideal to have a comparator from which to identify change. 
Changes may be measured relative to the outcomes for: non-ADF formulations of the same opioid 
prior to introduction (a counterfactual scenario, as in the case of a reformulation); a generic product 
equivalent in dosage, strength, route of administration, intended use, effects, and safety but lacking 
ADF properties; or to a similar but non-ADF opioid comparator (in the case of a new formulation) 
following ADF introduction. Where no historical or current non-ADF equivalent exists, multiple 
comparators with the same active moiety and/or similar levels of utilisation and rates of extra-
medical use at baseline may be appropriate (44). Consideration should be given to comparison of 
equianalgesic doses given variation in potency between various opioids (4, 45).  
 
There are a range of issues to consider when selecting a comparator. People who report extra-
medical use often report polysubstance use, making it difficult to attribute acute (e.g., overdose) and 
chronic (e.g., opioid dependence) outcomes to a single substance. Further, the comparator in 
secondary data can only be as specific as the smallest possible unit. For example, data sources which 
code according to International Classification of Disease (46) (e.g., hospital separations) record only 
‘pharmaceutical opioid’, failing to differentiate opioid type, formulation and strength (Table 2). 
Consequently, a priori selection and justification of comparators is critical, and multiple comparators 
may be appropriate where measuring multiple outcomes and using various data sources (4).  
 
 
Duration of monitoring 
The duration of monitoring may depend on the study design, data source(s), outcome(s) of interest, 
and time for uptake of the ADF (including substitution of the non-ADF with the ADF in dispensing 
where a reformulation is released). In the event of a reformulation, the FDA (4) states that that the 
baseline ‘pre’ introduction and observational ‘post’ introduction periods should be long enough to 
detect outcomes which may be rare or which have large uncertainty (due to bias or variability). 
Whilst the aforementioned factors (i.e., study design and time for uptake of the ADF) make it 
difficult to propose a uniform minimum monitoring period, the duration of the pre- and post-periods 
should allow sufficient time to evaluate whether extra-medical opioid use occurs with exposure to 
the ADF, with clear justification of the duration of the monitoring period. Yet, it is acknowledged 
that assessing appropriate duration of monitoring is complex, particularly with low-uptake in 
prescribing of ADFs and the implications of this for detecting low-frequency outcomes.  
 
Statistical analytic plan  
Both guidance documents (4, 11) highlight that the statistical analysis plan should be written before 
commencing data collection or before commencing analysis where using existing data (4, 45). To 
maximise transparency, this analytic plan should include a priori power and sample size analyses 
calculated on detecting a change in primary outcomes. It is acknowledged though that a priori 
identification of power for studies aimed at signal detection (i.e., measurement of any occurrence of 
an event in the population) may be challenging. Efforts to pre-specify and justify the denominator 
used to calculate change in each outcome across each data source will also enhance transparency. 
To illustrate, in the case of primary data collection it may be appropriate to pre-specify whether risk 
of extra-medical use will be estimated based on the total group exposed to pharmaceutical opioids 
or on the group reporting extra-medical use. In both instances, these groups can be defined; in the 
first instance, as total prescriptions, number of individuals receiving prescriptions, or number of 
dosage units dispensed (or another unit of total exposure); and in second instance, as number 
reporting using a greater dose than recommended, non-prescribed use, or tampering of the specific 
formulation or any opioid.  
 
The key aim is to identify outcomes associated with, and attributable to, ADF introduction (44). This 
is difficult when there are contemporaneous changes in the pharmaceutical opioid market, illicit 
drug market, and in prescribing practices which also may have impacts on extra-medical opioid use 
and harms. Further, there is some debate around how to identify a ‘meaningful’ reduction in extra-
medical use and harms, including whether there should be guidance on a minimum effect size 
 
observed. In evaluating possible causality, results could be framed using the logic of Bradford Hill as 
a guide (see 47 as an example), including: strength of associations (strength of relationship between 
exposure and outcome), consistency of findings (reproducibility across different people, settings, 
and samples), temporality of exposure and outcome (exposure precedes occurrence of outcome) 
and biological gradient (greater or lesser exposure leading to greater incidence of the outcome – 
noting that in some instances the exposure-outcome relationship can be more or less complex) (48). 
It is important that these criteria are not treated as a ‘checklist’ for causality, and rather as a guide 
for considering findings within and across studies (49). Indeed, there should be some consideration 
of competing interventions as an explanation given deployment of other strategies to address 
pharmaceutical opioid extra-medical use and harms (50).  
 
STUDY CONDUCT, GOVERNANCE AND REPORTING  
The following sections overview proposals specific to the conduct, governance and reporting of post-
marketing studies of ADFs (Table 3). We summarised published post-marketing studies of ADFs 
identified in a recent systematic review (5) to identify key components of conduct, governance and 
reporting which are recommended for observational study designs (51) (see Table 4). As can be seen 
there was variation across studies, and across the different facets of study conduct and reporting, in 
the extent to which six features of those were noted in the studies.  We explore these features 
further below.   
 
Funding and Industry Involvement 
All products which have been approved for an ADF label in the US must be evaluated post-market 
introduction, and the findings reported to the FDA (52). This regulatory requirement places the onus 
for establishing an evidence base regarding safety and effectiveness on the pharmaceutical 
company. However, there is an inherent conflict of interest where the company conducts such 
research themselves (53, 54). We acknowledge that regulatory processes have been put in place, in 
part, to address this issue. Ideally though, ADF post-marketing studies would be conducted at arms-
length from commercial interests. Regardless of funding source, it is advisable that study design, 
conduct and reporting for ADFs should undergo independent review (as detailed below) at multiple 
stages throughout the study. As per standard reporting guidelines (51), the name of the funder, their 
role in all aspects of study design, conduct, analysis, and reporting, and any other perceived conflicts 
of interests (including any other industry support received by the investigators) should be explicitly 
disclosed in all dissemination using standard reporting forms. 
 
 
Study advisory committee 
An advisory (or expert) committee is a common component of clinical trials or large-scale 
observational studies. An advisory committee sits separate from the project team: questioning, 
advising, and troubleshooting to ensure rigorous study design, conduct, and reporting under agreed 
upon terms of reference (55, 56). This group may form an important component of studies of 
pharmaceutical opioid ADFs by providing an additional level of monitoring and quality assurance; 
lending expertise in various study designs and data sources; and ensuring concerns and priorities at 
the community level are raised through consumer representation.  
 
Ideally, the committee would represent the interests of all parties involved in the research, including 
the research team, independent experts, consumers, and broader community. If feasible, the 
committee should include members who are independent of industry and the research team, and 
who provide a mix of statistical, clinical, epidemiological and lay/consumer backgrounds, including 
individuals with training in pharmaceutical science. This committee can review the study protocol, 
statistical analysis plan, data monitoring plan, questionnaires and other data collection tools prior to 
commencement; amendments to the aforementioned throughout the project; and the 
dissemination and publication plan at the conclusion of data collection.  
 
Protocol publication  
Increasingly, peer-review journals are now requesting submission of a prospectively published 
protocol or, at a minimum, a prospective statistical plan, for observational studies (57, 58). A study 
protocol prospectively details the data sources, populations of interest, study outcomes, choice of 
denominators, choice of opioid comparators, duration of monitoring, and statistical analytic plan 
(including power analyses). Although protocols for post-marketing studies of opioid ADFs may need 
to be submitted to regulatory bodies (4), ideally they should also be published in a public registry 
and/or in a legitimate independent peer-reviewed academic journal prior to study commencement 
(59). Published study protocols improve ethical conduct, minimise selective publication and selective 
reporting of results by comparison against the original study aims and analytic plan, and avoid 
unnecessary duplication of research (60). This transparency is particularly critical for research 
involving pharmaceutical drugs, where there is additional concern around publication bias and 
selective reporting. Essential to this process is inclusion of a link to the published protocol in all 
subsequent dissemination; justification of deviations from the protocol; and progress updates and 
reports of findings in any databases where the study protocol is available.  
 
 
Reporting study findings 
Investment in research, participant burden, and possible impacts on practice, policy, and future 
research underlie an ethical obligation to publish study findings (60). This requires dissemination of 
research findings to the broader community, and not just to regulatory bodies as per ADF reporting 
requirements. However, reviews of pharmaceutical research have indicated that a substantial 
number of post-marketing studies are never published or, where results are not positive, published 
at a delay or with selective reporting of findings (61). Findings should ideally be communicated to 
the research community via a legitimate independent peer-reviewed (and where possible, open 
access) academic journal (authored according to standard criteria for authorship; 51, 62), and by 
making study reports submitted to regulatory bodies publicly accessible.  
 
RECOMMENDATIONS 
We outline a series of proposals for ADF post-marketing research. We advocate that all parties 
should be working towards more detailed guidelines on both the conduct and reporting of ADF post-
marketing studies, building on existing guidance documents (4, 45), public workshops and forums on 
opioid ADFs (35), and the proposals raised in this paper. These reporting guidelines could include a 
checklist that studies are reported against, including justification of choice of study design, data 
source, population, comparator, duration of monitoring, analytic plan, and weighting of causal 
evidence within all dissemination related to the study. Guidelines can only improve research quality 
and enhance transparency. Thus, we believe that this recommendation can only serve to strengthen 
this field of research.    
 
CONCLUSIONS 
ADFs are a relatively new strategy in the response to increasing pharmaceutical opioid extra-medical 
use and harms. The best approaches for monitoring effectiveness have not been clearly delineated 
and are subject to considerable debate. Yet, the importance of progressing guidance for this field is 
essential given: increasing pharmaceutical opioid extra-medical use and harms; greater push to 
employ ADFs as a strategic response (10); insufficient evidence to conclude a net health benefit or 
harm from ADFs (5); and, of concern, preliminary economic modelling suggesting that healthcare 
costs associated with ADFs may actually be higher than non-ADF products (5). Monitoring of ADFs is 
complex and challenging, particularly when attempting to detect low-frequency events. The 
proposals outlined here might not be feasible in all research contexts and without appropriate 
resourcing, and other approaches not outlined here could also be borrowed from traditional and 
contemporary post-marketing surveillance approaches. Yet, we believe that this manuscript outlines 
 
useful recommendations in striving for best practice in study methods, conduct, design and 
governance. This work also reinforces the necessity for more detailed guidelines for ADF post-
marketing studies, to enhance study quality, transparency, and confidence in research findings.    
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Table 1. Example Study Designs, Data Types, Populations, and their Utility 
Design 
Secondary or 
primary data 
General or 
sentinel 
population 
Sensitivity 
Capacity to 
identify rare 
events 
Signal detection or 
risk quantification 
Group-level or 
individual-
level change 
Timeliness 
Time series 
Primary 
General Low Low 
Risk quantification 
 
No 
Moderate 
Sentinel high-risk High Moderate 
Secondary 
General Low Low 
Signal detection High 
Sentinel high-risk High Moderate  
Cross-sectional 
Primary 
General Low 
Low Risk quantification Moderate 
Sentinel high-risk High 
Secondary 
General Low Low 
Signal detection High 
Sentinel high-risk High Moderate  
Cohort 
Primary 
General Low Low 
Risk quantification Yes 
Moderate 
Sentinel high-risk High Moderate 
Secondary 
General Low Low 
High 
Sentinel high-risk High Moderate 
Note. Signal detection or risk quantification: the former is defined as measurement of any occurrence of the event, whereas risk quantification is defined 
as measurement of the rate of the event amongst the total sample who were at risk of the event.  Capacity to identify rare events: is determined based on 
whether it targets high risk groups for the event, sample size (statistical power) to identify events, and the variable level of detail in secondary data sources 
to capture data related to these events. Sensitivity: ability to detect change in events. Timeliness: ability to access data regularly to quickly detect change in 
events. This table lists several example study designs; other study designs (e.g., self-controlled designs) not listed here could also be considered for post-
marketing studies of ADFs.  
 
 
Table 2. Proposed Capacity to Measure Core Outcomes for ADF Post-Marketing Studies using Secondary Data Sources 
 Exposure Market Features Extra-Medical Use Harms 
 
Any 
use 
Prescribe
d use via 
intended 
route 
Illicit 
availability 
Street 
price 
Use more 
than 
recommen
ded by 
prescriber 
Non-
prescribe
d 
(diverted 
use) 
Tamperin
g 
Attractive-
ness for 
tampering 
Use via 
routes 
other than 
intended 
Extra-medical 
use of other 
pharmaceutic
al opioids 
Illicit 
drug use   
Dependent 
use and 
help-
seeking 
Non-fatal 
overdose 
Other 
acute 
harms 
(e.g., 
injection-
related 
injuries 
and 
diseases) 
Fatal 
overdose 
and other 
mortality 
related to 
opioids 
Manufacturer and 
sales data 
 
 
  
 
   
 
 
  
  
 
Medical and 
prescription claims 
and dispensing data 
 
 
  
 
   
 
 
  
  
 
Prescription drug 
monitoring program 
data 
 
 
  
 
   
 
 
  
  
 
Ambulance data                
Emergency 
department data 
 
 
  
 
   
 
 
  
  
 
Hospital centre data                
Poison 
information/control 
centre data 
 
 
  
 
   
 
 
  
  
 
Adverse event 
reporting data 
 
 
  
 
   
 
 
  
  
 
Needle-syringe 
program data 
 
 
  
 
   
 
 
     
Law enforcement 
seizure data 
 
 
  
 
   
 
 
  
  
 
Law enforcement 
arrest data 
 
 
  
 
   
 
 
  
  
 
Drug treatment data                
Drug and alcohol 
treatment helpline 
call data 
 
 
  
 
   
 
 
     
Mortality data (incl. 
coronial 
investigations) 
 
 
  
 
   
 
 
  
  
 
Web-based drug 
market and related 
sites monitoring   
 
 
  
 
   
 
 
  
  
 
 
  
 
 
KEY TO PATTERNS 
  Measures outcome related to any pharmaceutical opioid    
Measures outcome related to specific opioid type (e.g., morphine)    
Measures outcome related to specific opioid type plus specific formulation (including strength, e.g., 80mg ADF product)   
 
 
 
 
Table 3. Proposals for Study Conduct, Governance, and Reporting of Post-Marketing Studies of 
Pharmaceutical Opioid ADFs 
Funding, role 
of funders, 
and conflicts 
of interest 
 Funded by industry but the design, conduct and reporting should occur 
independent of industry where feasible (e.g., untied educational grant) 
 All dissemination related to the study should explicitly declare funding, and 
the role of funders 
 All dissemination related to the study should explicitly declare any conflicts 
of interest, including any other sponsorship or support from industry  
Advisory 
committee 
 Establish an advisory committee including membership that is independent 
of the research team and funders who advise on study design, conduct and 
reporting 
 Ensure representation from researchers, clinicians, and consumers  
 Meet prior to data collection to overview study protocol and data 
collection materials, and analytic plan. 
 Meet subsequent to data collection (with other meetings as needed) to 
discuss protocol variations, publication plan, and dissemination of findings 
Protocol    Include full details and justification of each element of study design  
 Include power analyses to confirm sufficient statistical power to detect 
changes in primary outcomes prior to data collection where relevant 
 Ensure the protocol undergoes independent peer-review  
 Publish the protocol prospectively (open-access where possible) in an 
independent public registry and/or in a journal article where it undergoes 
peer-review 
 Link to protocol in all subsequent dissemination 
Access to 
study results 
 Ensure findings are reported and in an open-access or in a publicly-
accessible format where undergo peer-review 
 Report findings according to relevant guidelines (e.g., STrengthening the 
Reporting of Observational studies in Epidemiology (STROBE) statement 
(51), Reporting of studies Conducted using Observational Routinely-
collected Data (RECORD) statement (62)) 
 Adopt standard definitions of authorship (e.g., International Committee of 
Medical Journal Editors authorship guidelines (63)) 
 Disclose individual investigator contributions to study design, conduct and 
reporting 
 
 
Table 4. Review of Reporting of ADF Post-Marketing Studies Identified in a Recent Systematic Review 
Study 
Publication 
Year 
Funded by 
industry 
Declares role 
of funding 
source1 
Declares 
author 
conflicts of 
interest 
Declares 
protocol 
publication or 
published 
priori analysis 
plan 
Declares a 
priori study 
registration 
Published 
findings 
open-
access 
Butler, et al. 
(13) 
2013 Yes 
Partly  
(reporting 
only) 
Yes Not specified Not specified No 
Cassidy, et al. 
(14) 
2014 Not specified Not specified Yes Not specified Not specified No 
Chilcoat, et al. 
(15) 
2016 Yes 
Partly  
(reporting 
only) 
Yes Not specified Not specified Yes 
Cicero , et al. 
(18) 
2012 No Yes Yes Not specified Not specified Yes 
Cicero and Ellis 
(16) 
2015 Yes Yes Yes Not specified Not specified Yes 
Cicero, et al. 
(17) 
2016 
Yes 
(indirectly) 
Not specified Yes Not specified Not specified No 
Coplan, et al. 
(19) 
2013 Yes Not specified Yes Not specified Not specified Yes 
Coplan, et al. 
(64) 
2016 Yes Not specified Yes Not specified Not specified Yes 
Degenhardt, et 
al. (20) 
2015 Yes Yes Yes Yes Not specified No 
Havens, et al. 
(21) 
2014 Yes Yes Yes Not specified Not specified No 
Hwang, et al. 
(22) 
2015 No Yes Yes Not specified Not specified No 
Jones, et al. (23) 2016 Not specified Not specified Yes Not specified Not specified No 
Larochelle, et al. 
(24) 
2015 No Yes Yes Not specified Not specified Yes 
Larance, et al. 
(38)* 
2018 Yes Yes Yes Yes Not specified No 
Michna, et al. 
(25) 
2014 Yes Not specified Yes Not specified Not specified Yes 
Peacock, et al. 
(26) 
2015 Yes Yes Yes Yes Not specified No 
Rossiter, et al. 
(27) 
2014 Yes Not specified Yes Not specified Not specified Yes 
Sankey, et al. 
(28) 
2016 Not specified Not specified 
Not 
specified 
Not specified Not specified No 
Schaffer, et al. 
(39) 
2018 No Yes Yes Not specified Not specified Yes 
Sessler, et al. 
(29) 
2014 Yes Not specified 
Not 
specified 
Not specified Not specified Yes 
Severtson, et al. 
(30) 
2013 
Yes 
(indirectly) 
Not specified Yes Not specified Not specified No 
Severtson, et al. 
(31) 
2016 
Yes 
(indirectly) 
Yes Yes Not specified Not specified Yes 
Note. We wish to acknowledge the work of the authors of a recently published systematic review 
who identified the studies listed here (5); papers notated with a * were published subsequent to the 
review and identified by the current authorship team. Poster abstracts were not included in the 
current analysis. 1 The authors must declare at a minimum the role the funding source played in 
study design, conduct, and reporting. STROBE: STrengthening the Reporting of OBservational Studies 
in Epidemiology guidelines (51). 
 
 
  
 
Figure 1. Key outcomes 
Exposure  
 Any use (i.e., regardless of route/prescribing) 
 Prescribed use via routes of administration as intended 
Market features 
 Street price 
 Illicit availability 
Extra-medical use (i.e., use outside the bounds of a medical professional’s advice) 
 Use a greater dosage than recommended by prescriber 
 Use non-prescribed pharmaceutical opioid  
 Tampering (crushing, dissolving, preparing for injection, etc)  
 Attractiveness (ease of tampering, ease of injecting, drug liking, etc)  
 Use via non-intended routes of administration (chew, snort, smoke, inject)  
Associated Harms 
 Extra-medical use of other pharmaceutical opioids 
 Used illicit drugs 
 Dependent use (‘addiction’)  
 Non-fatal overdose 
 Other acute harms (e.g., injection-related injuries and diseases) 
 Fatal overdose and other related causes of death  
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